Henry Han (@HanCardiomd) header
Henry Han (@HanCardiomd) profile picture

Cardiologist MBBS, MD, FACC, FESC | Physician-Sci & Researcher MPH, DMSc | #HeartFailure 🧑‍⚕️| #HFA Committee @escardio | Content Catalyst @TCTMD

USA | Earth 🌎
Joined July 2017
Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)
What’s new in heart failure? September 2026 academic.oup.com/eurjhf/adva… @ESC_Journals #EJHF @EJHFEiC @GianluSava
8
76
1
217
10,430
Henry Han retweeted
I still tend to associate BNP assays with random acts of kindness and blindness. Most lab results aren’t delivered with these qualifications and the often only carry critical values, so implementation science falls down. Furthermore this research “General and Exertional Fatigue, Quality of Life, and Risk of Incident Clinical Heart Failure in Those With Pre‐heart Failure in the ARIC Study” shot significant holes in the use of natriuretic peptides in screening. ahajournals.org/doi/10.1161/…
1
2
125
Henry Han retweeted
Ischemic Mitral Regurgitation: A Changing Paradigm Contemporary management of iMR ahajournals.org/doi/10.1161/… @CircAHA
1
22
59
3,831
Henry Han retweeted
#Cangrelor versus crushed #ticagrelor in #AMI complicated by cardiogenic shock (#DAPT-SHOCK-AMI) DAPT-SHOCK-AMI: First RCT comparing #P2Y12i strategies in AMI-CS. 📍Platelet inhibition: 100% vs 22% (p<0.0001), favoring cangrelor. 📍30-day clinical outcomes: 38% vs 41%; non-inferiority not demonstrated (P=0.13). 📍Major bleeding: 6% vs 5%. sciencedirect.com/science/ar… @TheLancet
2
23
81
5,964
Henry Han retweeted
Novel opportunities to tackle #HeartFailure with natriuretic peptides academic.oup.com/eurheartj/a… @ESC_Journals @ehj_ed
2
17
49
3,332
SELLAS Life Sciences Announces Positive Pivotal Phase 3 #REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with #AML ir.sellaslifesciences.com/ne… mskcc.org/news/vaccine-impro…
5
538
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced. wapo.st/4t6oIRy
119
1,594
316
6,178
833,748
Impact of age on implementation and tolerability of #GDMT in patients with #HFrEF(TITRATE-HF) academic.oup.com/eurjhf/adva… @ESC_Journals @EJHFEiC
1
4
18
1,418
Novel opportunities to tackle #HeartFailure with natriuretic peptides academic.oup.com/eurheartj/a… @ESC_Journals @ehj_ed
2
17
49
3,332
#Cangrelor versus crushed #ticagrelor in #AMI complicated by cardiogenic shock (#DAPT-SHOCK-AMI) DAPT-SHOCK-AMI: First RCT comparing #P2Y12i strategies in AMI-CS. 📍Platelet inhibition: 100% vs 22% (p<0.0001), favoring cangrelor. 📍30-day clinical outcomes: 38% vs 41%; non-inferiority not demonstrated (P=0.13). 📍Major bleeding: 6% vs 5%. sciencedirect.com/science/ar… @TheLancet
2
23
81
5,964
#Cangrelor for myocardial infarction-related cardiogenic shock thelancet.com/journals/lance… @TheLancet
3
4
487
Ischemic Mitral Regurgitation: A Changing Paradigm Contemporary management of iMR ahajournals.org/doi/10.1161/… @CircAHA
1
22
59
3,831
Henry Han retweeted
Wow! Thanks for sharing this @HanCardiomd highly appreciated!
1
2
319
#Vasodilation in heart failure with reduced ejection fraction: right patient, right time? #HFrEF @ESC_Journals @ehj_ed @WilfriedMullens @PieterMartensMD academic.oup.com/eurheartj/a…
2
57
191
7,936
Practice changing trials: focus on prevention, #HeartFailure, interventional cardiology, and rehabilitation academic.oup.com/eurheartj/a… #EHJ @ehj_ed @ESC_Journals
7
14
1,417
Henry Han retweeted
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels. 1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients. 2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly. 3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering. 4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se. 5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent. 6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason. 7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future. 8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a). I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field. And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies, I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future. With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future. Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
52
121
18
546
63,092
Evaluating the role of lower extremity elastic bandage in patients with acute decompensated heart failure academic.oup.com/eurjhf/adva… @HanCardiomd @AmrAbdin10 @GiuseppeGalati_
19
1
53
5,869
Now in @JACCJournals by #HFC member @JavedButler1 et al. A new study estimates the potential impact of recently approved cardiometabolic therapies and risk-based prevention strategies on the future burden of HF in the U.S. jacc.org/doi/10.1016/j.jchf.…
1
3
8
609
Honored to receive the Sir William Osler Young Investigator Award from the Interurban Clinical Club, founded by Osler in 1905. 🏅 A legacy of discovery & mentorship I’m grateful to share with our mentors, collaborators & trainees. ❤️ @Yale
2
6
31
2,791
Henry Han retweeted
Can one risk equation predict two HF phenotypes? PREVENT-HF predicted both #HFpEF and #HFrEF across community cohorts and health system samples, with modestly better discrimination for HFpEF. #ScientificSessions26 @AHAScience ahajrnls.org/4zBqgoW
6
8
17
2,875